OncoMatch

OncoMatch/Clinical Trials/NCT05850234

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Is NCT05850234 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GC012F (AZD0120) for relapsed/ refractory multiple myeloma.

Phase 1/2RecruitingAstraZenecaNCT05850234Data as of May 2026

Treatment: GC012F (AZD0120) — This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 3 prior lines

Must have received: proteasome inhibitor

Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody.

Must have received: immunomodulatory drug

Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody.

Must have received: anti-CD38 antibody

Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody.

Cannot have received: allogeneic stem cell transplant

Exception: allowed if >6 months before apheresis and off all immunosuppressive medications for 6 weeks without signs of GVHD

An allogenic stem cell transplant within 6 months before apheresis. Subjects who received an allogeneic transplant must be off all immunosuppressive medications for 6 weeks without signs of graft-versus-host disease (GVHD).

Cannot have received: autologous stem cell transplant

Exception: allowed if >12 weeks before apheresis

An autologous stem cell transplant ≤12 weeks before apheresis

Lab requirements

Blood counts

Adequate bone marrow and organ function assessment at screening according to the hematological parameters listed in the CSP

Kidney function

Adequate organ function assessment at screening according to the renal parameters listed in the CSP

Liver function

Adequate organ function assessment at screening according to the hepatic parameters listed in the CSP

Cardiac function

Exclusion of NYHA stage III or IV CHF, MI or CABG ≤6 months, history of clinically significant ventricular arrhythmia or unexplained syncope, history of severe non-ischemic cardiomyopathy

Adequate bone marrow and organ function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP; The following cardiac conditions: NYHA stage III or IV CHF, MI or CABG ≤6 months, history of clinically significant ventricular arrhythmia or unexplained syncope, history of severe non-ischemic cardiomyopathy [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Birmingham, Alabama
  • Research Site · Phoenix, Arizona
  • Research Site · La Jolla, California
  • Research Site · Los Angeles, California
  • Research Site · San Francisco, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify